Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Afatinib (Primary) ; Docetaxel
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 06 Feb 2019 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
- 06 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 03 Oct 2018 Status changed from recruiting to active, no longer recruiting.